(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 2 October 2003 (02.10.2003)

PCT

(10) International Publication Number WO 03/080646 A2

(51) International Patent Classification7:

C07K

- (21) International Application Number: PCT/US03/06679
- (22) International Filing Date: 4 March 2003 (04.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: 60/361,670
- 4 March 2002 (04.03.2002) US
- (71) Applicant (for all designated States except US): MED-ICAL COLLEGE OF OHIO [US/US]; 3000 Arlington Avenue, Toledo, OH 43614 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SWIERCZ, Rafal [US/US]; 1355 Oak Hill Ct., Apt. 69, Toledo, OH 43614

(US). SELMAN, Steven, H. [US/US]; 4534 Granitville Court, Toledo, OH 43615 (US). JANKUN, Jerzy [US/US]; 7014 Oakshade Road, Sylvania, OH 43560 (US).

- (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON

GARTTCCTGCAGCTCAGCAGCCGCCGCCAGAGCAGGACGAACCGCCAATCGCAAGGCACC CTTAAGGACGTCGAGTCGTCGGCGGCGGCTCTCGTCCTGCTTGGGGGTTAGCGTTCCGTTGG TCTGAGAACTTCAGGATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCC AGACTCTTGAAGTCCTACGTCTACAGAGGTCGGGAGTGGACGGGATCAGGACCCGGACCGG O'H S PALTCLV LG LA CTTOTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCATCCTACGTGGCCCACCTGGCC 121 GARCAGRARCCACTTCCCAGACGACACCGTGGTAGGGGGTAGGATGCACCGGG L V P G B G B A | V E B P P S Y V A E L A 13

Start Mature Protein AGTETUAAGECCCACTCCCACAAAGTCGTCCACCGCGCCCCGGAGGTTCCTGG F S V R V F Q Q V A Q A S K D R W OTTTTCTCACCCTATOGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGA CAMADAGTOGOATACEEGACGOGAGCEACAAGCGGTACGAGGTEGACTGTTGTGETC SPYGVÄSVLAMLOLTTGG 52 CARACTCAGCAGCAGATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCC CTTTGGGTCGTCTAAGTTCGTCGATACCCTAAGTTCTAACTACTGTTCCCGTACCG CCCGCCCTCCGGCXTCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGC 361 GGGGGGGGGCCOTAGACATOTTCCTCGAGTACCCCGGTACCTTGTTCCTACTCTAGTCG ALRELTEELNGP ACCACAGACGCGATCTTCGTCCAGCGGGATCT"AAGCTGGTCCAGGGCTTCATGCCCCAC TGGTGTCTGCGCTAGAAGCAGGTCGCCCTAGACTTCGACCAGGTCCCGAAGTACGGGGTG TIDAIFVQRDLEXE VQOFEAGGAGAGGAGAGGGGAGAGAGGCC AAGAAGTCCGACAAGGCCTCGTGCCAGTTCGCTCACCTGAAAAGTCTCCAC PRLFRSTVEQVDFSEVERA 132 AGATTCATCATCATGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTT TOTALOTAGTAGTTACTCACCCACTTCTGTGTGTGTTTTCCATACTAGTCGTTGAACGAA

(57) Abstract: The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.

WO 03/080646 A2